HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bautsch, W. Articles by Köhl, J. Search for Related Content PubMed PubMed Citation Articles by Bautsch, W. Articles by Köhl, J. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Asthma

Cutting Edge: Guinea Pigs with a Natural C3a-Receptor Defect Exhibit Decreased Bronchoconstriction in Allergic Airway Disease: Evidence for an Involvement of the C3a Anaphylatoxin in the Pathogenesis of Asthma¹

Wilfried Bautsch^2,*, Heinz-Gerd Hoymann, Qiuwang Zhang^*, Ivo Meier-Wiedenbach^*, Ursula Raschke^*, Robert S. Ames, Bettina Sohns^*, Nicole Flemme^*, Andreas Meyer zu Vilsendorf, Melanie Grove^*, Andreas Klos^* and Jörg Köhl^*

^* Institute of Medical Microbiology and Department of Transplantation Surgery, Medical School, Hannover, Germany; Fraunhofer Institute of Toxicology and Aerosol Research, Hannover, Germany; and SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406

	Abstract

Top Abstract Introduction Materials and Methods Results and Discussion References

 
Asthma is a major cause of morbidity worldwide with prevalence and severity still increasing at an alarming pace. Hallmarks of this disease include early-phase bronchoconstriction with subsequent eosinophil infiltration, symptoms that may be mimicked in vivo by the complement-derived C3a anaphylatoxin, following its interaction with the single-copy C3aR. We analyzed the pathophysiological role of the C3a anaphylatoxin in a model of experimental OVA-induced allergic asthma, using an inbred guinea pig strain phenotypically unresponsive to C3a. Molecular analysis of this defect revealed a point mutation within the coding region of the C3aR that creates a stop codon, thereby effectively inactivating gene function. When challenged by OVA inhalation, sensitized animals of this strain exhibited a bronchoconstriction decreased by 30% in comparison to the corresponding wild-type strain. These data suggest an important role of C3a in the pathogenesis of asthma and define a novel target for drug intervention strategies.

	Introduction

Top Abstract Introduction Materials and Methods Results and Discussion References

 
Asthma is a major health problem worldwide. The prevalence and severity have been increasing at an alarming pace in recent decades; up to 25% of children under the age of 14 years have asthma (1). The disease is triggered by Ag inhalation and characterized by an early phase of bronchoconstriction, followed by a late-phase airway hyperresponsiveness and excessive mucus production associated with the appearance of eosinophils and T_H2 lymphocytes in the airways. The early airway response is associated with cross-linking of IgE bound to FcR on mast cells inducing degranulation (2). Thus, IgE is considered to be a major trigger of asthma, a view recently supported by the therapeutic value of a humanized mouse anti-IgE mAb (3). However, other mechanisms also contribute to the disease as shown by the strong association of asthma with several genetic susceptibility genes in the human genome, some of which seem to act independently of serum IgE or other measures of atopy (4, 5). The limited knowledge of the pathophysiology of asthma hampers the development of more effective therapies for this disease.

Certain important features of asthma can be modeled in mice, rats, and guinea pigs. OVA-sensitized animals challenged with aerosolized allergen react with an immediate, early-phase bronchoconstriction associated with histamine release and peptidoleukotriene secretion from mast cells, and a late-phase bronchial hyperreactivity associated with a high eosinophil content in the lung, although the molecular details of this association are not well understood. Using such models, allergic airway disease could be demonstrated in B cell deficient mice, clearly showing that non-IgE related mechanisms are operative in these animal models, too (6).

The C3a anaphylatoxin is a potent proinflammatory mediator that is generated in the early phase of an inflammatory reaction by proteolytic cleavage of the complement component C3 (7). It promotes multifarious in vitro reactions that include bronchoconstriction (8, 9), edema formation, as well as attraction and activation of mast cells (10, 11) and eosinophils (12, 13); but it has no effect on neutrophil chemotaxis. C3a binds to a single ligand-specific receptor, the C3aR, which has only recently been cloned from several species including man, mouse, rat, and guinea pig (14, 15, 16, 17, 18, 19). The high potency, the generation right at the beginning of an inflammatory reaction and the characteristic activity pattern suggest a central involvement of C3a in the pathophysiology of allergic disease states, like asthma. Indeed, C3a levels are increased in the bronchoalveolar lavage fluid of asthma patients (20) where they could be generated by two different routes: immune complex formation involving Abs of the IgM/IgG class (but not IgE), or proteolytic cleavage of complement component C3 by the neutral tryptase, the major protease present in mast cell granules (21). But experimental evidence for such an involvement has not yet been obtained due to the absence of well-characterized C3aR-defective animal models or potent receptor antagonists.

Guinea pigs have been widely used to analyze the early bronchoconstriction phase following allergen inhalation, as these animals are exquisitely sensitive to airway Ag challenge; indeed, an antihistamine has to be administered before allergen challenge to prevent acute fatality. Consequently, these animals have also been used to analyze C3a-induced bronchoconstriction, which can be antagonized by cyclooxygenase inhibitors but not antihistamines (8) similar to the situation in humans. Although an inbred guinea pig strain, called C2BB/R^-, has been described that is nonresponsive to C3a in platelet-based assays (22), the molecular nature of this defect remained obscure and few animal studies have been performed with this strain (23).

	Materials and Methods

Top Abstract Introduction Materials and Methods Results and Discussion References

 
Materials

Guinea pigs of the inbred strains of C3aR-positive C2BB/R⁺ and C2BB/R^- were obtained from our own breeding stocks and kept in closed colonies. Human C3a was obtained from Advanced Research Technologies (San Diego, CA), and ¹²⁵I-labeled C3a from NEN (Boston, MA). Human embryonic kidney cells (HEK)³ 293 were cultured as described elsewhere (24).

Molecular analysis of the C3aR locus in strain C2BB/R^-

The coding region of the C3aR was amplified from guinea pig genomic DNA by PCR using oligonucleotide primers P1 (5'-GATACCATGTCAGTACGTG, position -105 to -87) and P2 (5'-CTTGGGCTCACTTTGTAGC, position +1546 to +1528), and both strands were sequenced. For demonstration of the presence/absence of the point mutation at position +955 within the C3aR coding sequence, a 1152-bp fragment was amplified from genomic DNA by PCR using oligonucleotide primers P3 (5'-CATTTAGCCATGGAGTCTTCC, position -9 to +12) and P4 (5'-CCAGCAGATAAGAAAGATGG, position +1143 to +1124). The fragment was digested with restriction endonucleases SspI and XbaI (New England Biolabs, Beverly, MA) according to the manufacturer’s instructions, and the fragments were visualized after agarose gel electrophoresis.

A polyclonal antiserum against the guinea pig C3aR was obtained by immunizing rabbits with the second extracellular loop of the C3aR fused to glutathion-S-transferase, following the procedures described previously (25). A 1:500 to 1:1000 dilution of the immune serum specifically recognized the guinea pig C3aR (but not the human C5aR) in transiently transfected HEK 293 cells by indirect immunofluorescence or flow cytometry (data not shown). The CG transition was introduced into position +955 of the guinea pig C3aR sequence by PCR-mediated site-directed mutagenesis, as described previously (24). Flow cytometry and binding assays were performed essentially as described elsewhere (24).

Sensitization and in vivo allergen challenge of guinea pigs

Animals of both sexes with an average weight of 600 ± 50 g (C2BB/R⁺: 618.4 ± 47.9 g, range 540–680 g, 7 female and 7 male; C2BB/R^-: 596.6 ± 54.8 g, range 503–709 g, 13 female and 7 male; at the day of allergen challenge) were used for the experiments. Guinea pigs were sensitized with an i.p. injection of OVA (10 µg plus 20 mg aluminum hydroxide in 0.5 ml saline) on day 0 and 7, followed by an inhalational boost on day 21, and the challenge on day 35. Thirty minutes before inhalational boost/allergen challenge, animals were given 5 mg/kg pyrilamine i.p. in saline. Lung function parameters were measured in four animals simultaneously (26) in whole-body double-chamber plethysmographs equipped with two pneumotachographs and two Validyne DP45–14 transducers each, using a modified method according to Pennock et al. (27) by means of a Buxco LS-20 system (Buxco Electronics, Sharon, CT). The OVA booster and challenge inhalations (1% in saline) were performed by means of the aerosol generation system Bronchy Type III (developed by the Fraunhofer Institute of Toxicology and Aerosol Research (Hannover, Germany; Refs. 26 and 28). Mass median aerodynamic diameter (geometric SD) of OVA was 1.2 (2.5) µm. Exposures were performed under continuous monitoring of the inhalation atmosphere using a gravimetrically calibrated air mantle aerosol photometer. After a 5-min adaptation, baseline (3 min), allergen challenge (8 min), and postchallenge values (12 min) of respiratory rate, tidal volume, and specific airway resistance (SRAW) were recorded in spontaneously breathing, awake animals. Results are expressed as percent increase above baseline averaged over a 20-min interval period (challenge plus post-challenge) and related to baseline. Therefore, the averaged values were much lower than the respective maximum values but were nearly independent of artifacts and more representative for the early allergic response.

Histochemistry, eosinophil peroxidase (EPO) measurement and Ab titer

Six hours later, the animals were killed by exsanguination and the pulmonary arteries were flushed with saline containing 10 mM EDTA. The right lobe of the lung was removed, chopped, and processed immediately to determine eosinophil numbers in the lung tissue using the EPO assay as described elsewhere (29). For histochemistry, the left lobe was either frozen in liquid nitrogen and stored at -70°C, or fixated in formaline. Cryostat sections (7.0 µm) or 2.0 µm sections of paraffin-embedded tissue were stained with hematoxylin-eosin according to standard techniques. Total IgG Ab titers of each animal were determined by ELISA using OVA-coated 96-well plates and goat anti-guinea pig IgG (1:10,000 dilution; Dianova, Hamburg, Germany) according to standard procedures. A threshold OD of 0.15 (2.5-fold buffer value; 1/6 of the total signal) was used for determination of the titer. Results are presented as group mean ± SEM. Untransformed data were analyzed using the Wilcoxon two-sample test (U test of Mann/Whitney); p < 0.05 was considered statistically significant.

	Results and Discussion

Top Abstract Introduction Materials and Methods Results and Discussion References

 
Strain C2BB/R^- carries a point mutation within the C3aR gene locus

To elucidate the contribution of the C3a anaphylatoxin to the development of asthma, we first analyzed the genetic defect in the phenotypically C2BB/R^- inbred guinea pig strain C2BB/R^- at a molecular level. Previously, we had cloned the coding sequence of the guinea pig C3aR from a genomic DNA library (18). Using primers directed against DNA sequences flanking the C3aR locus, the complete C3aR coding sequence was amplified and sequenced from genomic DNA of strain C2BB/R^-. As shown in Fig. 1A, the C2BB/R^- strain of guinea pigs harbors a single CT transition in position +955 of the C3aR that changes a CGA arginine codon into a TGA stop codon. This mutation introduces within the C3aR open reading frame a novel SspI endonuclease restriction site. As shown in Fig. 1B, this provides a convenient genetic assay to screen for the underlying genotype.

View larger version (80K): [in this window] [in a new window]   FIGURE 1. A point mutation in the C3aR coding region of strain C2BB/R-. Upper, DNA and protein sequence of wild-type and mutant guinea pig C3aR. The CT transition is indicated by an arrow; the novel SspI restriction site generated by this exchange is given in italics. Lower, Demonstration of the SspI restriction site in the C3aR coding sequence of strain C2BB/R-, but not C2BB/R+. A 1152-kbp PCR fragment of the C3aR coding sequence was amplified from genomic DNA of strain C2BB/R+ (lanes 1–3), C2BB/R- (lanes 4–6), or a plasmid containing the wild-type C3aR (lanes 7–9) and separated by gel electrophoresis either undigested (lanes 1, 4, 7) or digested with SspI (lanes 2, 5, and 8) or XbaI (lanes 3, 6, and 9). The SspI site in strain C2BB/R- is revealed by the size reduction of the PCR fragment (lane 5) while the released 200-bp fragment has diffused of the gel and is no longer visible. S, Size marker.

The mutation effectively inactivates the C3aR in strain C2BB/R^-

The C3aR is a single-copy gene that exhibits a unique feature among all G-protein coupled receptors: an unusually large second extracellular loop of >150 residues. The mutation found in the C3aR coding region of strain C2BB/R^- is located at the C-terminal end of this loop shortly before the beginning of the transmembrane helix V, thus effectively deleting 1/3 of the receptor. This would easily explain the complete unresponsiveness of this strain in the platelet C3a-mediated ATP release assay, an exquisitely sensitive and specific assay for anaphylatoxins (18). Interestingly, in guinea pigs, a second C3aR sequence has been described that lacks 35 amino acids in the second extracellular loop. However, this C3aR variant behaved identically with the wild-type receptor with respect to ligand binding and signal transduction properties (19). The mutation found in strain C2BB/R^- is located just C-terminal to and thus outside the proposed splicing region. Therefore, both putative C3aR isoforms should be affected in the C2BB/R^- strain.

To confirm the deleterious consequences of a deletion of the distal 1/3 in the C3aR, we introduced the same point mutation into the wild-type sequence of the guinea pig C3aR by site-directed mutagenesis, and functionally characterized both the wild-type and mutant genes after transient transfection into human HEK 293 cells. Using a polyclonal rabbit antiserum directed against the large second extracellular loop, a residual minor expression of the mutant C3aR on the cell surface was found by flow cytometry (Fig. 2A). However, no binding of radioiodinated C3a could be detected (Fig. 2B), confirming that this stop codon effectively inactivates the receptor. These data show that this guinea pig strain is a good model to analyze C3aR functions in vivo.

View larger version (28K): [in this window] [in a new window]   FIGURE 2. Analysis of the mutant guinea pig C3aR. A, Flow cytometry of HEK 293 cells transiently transfected either with the wild-type or mutant guinea pig C3aR and developed with a polyclonal antiserum against the second extracellular loop of the C3aR. Consistently, a slight shift of cells transfected with the mutant C3aR in comparison to the mock control or the preimmune serum was observed, indicating some residual expression of this mutant on the cell surface (n = 3). B, Competitive binding assay of transfected HEK 293 cells using radiolabeled C3a with (+) and without (-) addition of unlabeled C3a. Specific C3a binding was detected in cells transfected with the wild-type C3aR (1 2 ), but not the mutant C3aR (3 4 ) or the mock control (5 , 6 ) (n = 3).

To analyze the pathophysiological function of C3a in an allergic asthma model, animals of strains C2BB/R⁺ (wild-type C3aR) and C2BB/R^- were sensitized with OVA by intraperitoneal and inhalational immunization. Two weeks after the final boost, lung function parameters of spontaneously breathing animals in response to aerosolized OVA were recorded by whole-body plethysmography.

Both animal groups responded with a bronchoconstriction following OVA antigen inhalation. However, the increase in SRAW was significantly lower by 30% in the C2BB/R^- strain when compared with strain C2BB/R⁺ harboring a functional C3aR (Fig. 3). This result is also reflected in the respiratory rate, which compensatorily increased in both groups, but which was significantly more pronounced in C2BB/R⁺ animals (39.7% ± 9.2; mean ± SEM) than in the C3aR-negative animals (14.7% ± 21.8; p < 0.01; data not shown). Also, the prechallenge respiratory rate was slightly higher in the C3aR-negative group (142.3 ± 15.1 vs 121.6 ± 9.7 in C2BB/R⁺, p < 0.01) indicating that these animals took up even slightly more Ag than the C2BB/R⁺ group; all other lung function parameters were identical among both groups.

View larger version (21K): [in this window] [in a new window]   FIGURE 3. SRAW (percent increase above baseline) of OVA-sensitized guinea pigs of strain C2BB/R+ harboring a functional C3aR (n = 14) and C2BB/R- (n = 20) on allergen challenge averaged over 20 min. *, A significant decrease of 30% was observed in the C3aR defective strain (p < 0.05).

The eosinophil influx in strain C2BB/R^- is not decreased 6 h after allergen challenge

The late response in asthma is characterized by an influx of cells, predominately eosinophils, into the lung tissue (strikingly increased already 6 h after allergen challenge) and bronchiolar lavage fluid (after 24 h) (29). Because C3a is a known eosinophil chemoattractant (12, 13), we analyzed lung sections 6 h after allergen challenge. A strong eosinophil influx into the lung was observed in both animal strains, which was most prominent around the bronchioli (Fig. 4). As a quantitative measure, we determined the EPO content in lung homogenates. No significant difference between the two animal groups was detected at this time point. We even observed a trend toward a higher EPO content in the C3aR-negative animals (data not shown), which might be explained, however, by the slightly higher Ag uptake in this group (see above).

View larger version (70K): [in this window] [in a new window]   FIGURE 4. Peribronchiolar infiltration of eosinophils 6 h after allergen challenge in strain C2BB/R+ (a) and C2BB/R- (b). (hematoxylin and eosin stain)

In summary, we describe a new animal strain to study the pathophysiological role of the C3a/C3aR system in vivo, i.e., an inbred guinea pig strain with a natural C3aR defect. In a model of OVA-induced allergic airway disease a reduced bronchoconstriction in the defective strain was observed, providing the first experimental evidence of a pathophysiological role of the C3a anaphylatoxin in vivo. While this paper was under consideration, a similar observation was reported by Humbles et al. (33) using a genetically engineered C3aR knockout mouse strain. These authors also observed an effect on bronchoconstriction (reduced late-phase airway hyperresponsiveness) in an OVA-induced asthma model, but no effect on eosinophil influx, in full agreement with our report. Taken together, these data underscore the importance of the complement-derived anaphylatoxins as proinflammatory mediators in disease pathogenesis and suggest a novel target for drug intervention strategies in human asthma.

	Acknowledgments

 
We gratefully acknowledge the technical expertise and helpful comments of R. Korolewitz (Fraunhofer Institute of Toxicology and Aerosol Research); M. Kuske, H. Hecker, and T. Tschernig (Medical School, Hannover, Germany); and the continuous strong support of the head of the Institute of Medical Microbiology, D. Bitter-Suermann (Hannover, Germany).

	Footnotes

 
¹ This work was supported by SmithKline Beecham Pharmaceuticals and a grant from the Sonderforschungsbereich "Chronische Entzündung" (to W.B.).

² Address correspondence and reprint requests to Dr. Wilfried Bautsch, Institute of Medical Microbiology, Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany.

³ Abbreviations used in this paper:HEK, human embryonic kidney; EPO, eosinophil peroxidase; SRAW, specific airway resistance.

Received for publication August 24, 2000. Accepted for publication September 6, 2000.

	References

Top Abstract Introduction Materials and Methods Results and Discussion References

 

1. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. 1998. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. Lancet 351:1225.[Medline]
2. Corry, D. B., F. Kheradmand. 1999. Induction and regulation of the IgE response. Nature 402:(Suppl.):B18.[Medline]
3. Milgrom, H., Jr R. B. Fick, J. Q. Su, J. D. Reimann, R. K. Bush, M. L. Watrous, W. J. Metzger. 1999. Treatment of allergic asthma with monoclonal anti-IgE antibody: rhuMAb-E25 study group. N. Engl. J. Med. 341:1966.[Abstract/Free Full Text]
4. The Collaborative Study on the Genetics of Asthma (CSGA). 1997. A genome-wide search for asthma susceptibility loci in ethnically diverse populations. Nat. Genet. 15:389.[Medline]
5. Moffatt, M. F., W. O. Cookson. 1997. Tumour necrosis factor haplotypes and asthma. Hum. Mol. Genet. 6:551.[Abstract/Free Full Text]
6. Hamelmann, E., K. Takeda, J. Schwarze, A. T. Vella, C. G. Irvin, E. W. Gelfand. 1999. Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes. Am. J. Respir. Cell. Mol. Biol. 21:480.[Abstract/Free Full Text]
7. Ember, J. A., M. Jagels, T. E. Hugli. 1998. Anaphylatoxins and biological responses. J. Volanakis, and M. Frank, eds. The Human Complement System in Health and Disease 241. Dekker, New York.
8. Stimler-Gerard, N. P.. 1086. Immunopharmacology of anaphylatoxin-induced bronchoconstrictor responses. Complement 3:137.[Medline]
9. Watson, J. W., J. M. Drazen, N. P. Stimler-Gerard. 1988. Synergism between inflammatory mediators in vivo: induction of airway hyperresponsiveness to C3a in the guinea pig. Am. Rev. Respir. Dis. 137:636.[Medline]
10. Legler, D. F., M. Loetscher, S. A. Jones, C. A. Dahinden, M. Arock, B. Moser. 1996. Expression of high- and low-affinity receptors for C3a on the human mast cell line, HMC-1. Eur. J. Immunol. 26:753.[Medline]
11. Nilsson, G., M. Johnell, C. H. Hammer, H. L. Tiffany, K. Nilsson, D. D. Metcalfe, A. Siegbahn, P. M. Murphy. 1996. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J. Immunol. 157:1693.[Abstract]
12. Daffern, P. J., P. H. Pfeifer, J. A. Ember, T. E. Hugli. 1995. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J. Exp. Med. 18:2119.
13. DiScipio, R. G., P. J. Daffern, M. A. Jagels, D. H. Broide, P. Sriramarao. 1999. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J. Immunol. 162:1127.[Abstract/Free Full Text]
14. Ames, R. S., Y. Li, H. M. Sarau, P. Nuthulaganti, J. J. Foley, C. Ellis, Z. Zeng, K. Su, A. J. Jurewicz, R. P. Hertzberg, et al 1996. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J. Biol. Chem. 271:20231.[Abstract/Free Full Text]
15. Crass, T., U. Raffetseder, U. Martin, M. Grove, A. Klos, J. Köhl, W. Bautsch. 1996. Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Eur. J. Immunol. 26:1944.[Medline]
16. Tornetta, M. A., J. J. Foley, H. M. Sarau, R. S. Ames. 1997. The mouse anaphylatoxin C3a receptor: molecular cloning, genomic organization, and functional expression. J. Immunol. 158:5277.[Abstract]
17. Fukuoka, Y., J. A. Ember, T. E. Hugli. 1998. Cloning and characterization of rat C3a receptor: differential expression of rat C3a and C5a receptors by LPS stimulation. Biochem. Biophys. Res. Commun. 242:663.[Medline]
18. Lienenklaus, S., R. S. Ames, M. A. Tornetta, H. M. Sarau, J. J. Foley, T. Crass, B. Sohns, U. Raffetseder, M. Grove, A. Hölzer, et al 1998. Human anaphylatoxin C4a is a potent agonist of the guinea pig but not the human C3a receptor. J. Immunol. 161:2089.[Abstract/Free Full Text]
19. Fukuoka, Y., J. A. Ember, T. E. Hugli. 1998. Molecular cloning of two isoforms of the guinea pig C3a anaphylatoxin receptor: alternative splicing in the large extracellular loop. J. Immunol. 161:2977.[Abstract/Free Full Text]
20. van de Graaf, E. A., H. M. Jansen, M. M. Bakker, C. Alberts, J. K. Eeftinck Schattenkerk, T. A. Out. 1992. ELISA of complement C3a in bronchoalveolar lavage fluid. J. Immunol. Methods 147:241.[Medline]
21. Schwartz, L. B., M. S. Kawahara, T. E. Hugli, D. Vik, D. T. Fearon, K. F. Austen. 1983. Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J. Immunol. 130:1891.[Abstract]
22. Bitter-Suermann, D., R. Burger. 1986. Guinea pigs deficient in C2, C4, C3 or the C3a receptor. Prog. Allergy 39:134.[Medline]
23. Regal, J. F., A. Klos. 2000. Minor role of the C3a receptor in systemic anaphylaxis in the guinea pig. Immunopharmacology 46:15.[Medline]
24. Crass, T., R. S. Ames, H. M. Sarau, M. A. Tornetta, J. J. Foley, J. Köhl, A. Klos, W. Bautsch. 1999. Chimeric receptors of the human C3a receptor and C5a receptor (CD88). J. Biol. Chem. 274:8367.[Abstract/Free Full Text]
25. Martin, U., D. Bock, L. Arseniev, M. A. Tornetta, R. S. Ames, W. Bautsch, J. Köhl, A. Ganser, A. Klos. 1997. The human C3a receptor is expressed on neutrophils and monocytes but not on B or T lymphocytes. J. Exp. Med. 186:199.[Abstract/Free Full Text]
26. Hoymann, H. G., U. Heinrich. 1998. Measurement of lung function in rodents in vivo. S. Uhlig, and A. E. Taylor, eds. Measurement in Pulmonary Research 1. Birkhäuser, Basel.
27. Pennock, B. E., C. P. Cox., R. M. Rogers, W. A. Cain, J. H. Wells. 1979. A noninvasive technique for measurement of changes in specific airways resistance. J. Appl. Physiol. 46:399.[Abstract/Free Full Text]
28. Hohlfeld, J., R. White, W. Koch, and U. Heinrich. 1992. A new aerosol generating device for use in animal physiology. Eur. Respir. J. 5(Suppl. 15):531.S.
29. Humbles, A. A., D. M. Conroy, S. Marleau, S. M. Rankin, R. T. Palframan, A. E. Proudfoot, T. N. Wells, D. Li, P. K. Jeffery, D. A. Griffiths-Johnson, et al 1997. Kinetics of eotaxin generation and its relationship to eosinophil accumulation in allergic airways disease: analysis in a guinea pig model in vivo. J. Exp. Med. 186:601.[Abstract/Free Full Text]
30. Fischer, W. H., T. E. Hugli. 1997. Regulation of B cell functions by C3a and C3a(desArg): suppression of TNF-, IL-6, and the polyclonal immune response. J. Immunol. 159:4279.[Abstract]
31. Werfel, T., K. Kirchhoff, M. Wittmann, A. Kapp, G. Begemann, O. Götze, J. Zwirner. 1999. Human T lymphocytes express the C3a receptor. Immunobiology 200:641. (Abstr.).
32. Danahay, H., K. J. Broadley, P. J. McCabe, A. T. Nials, S. Sanjar. 1999. Temporal relationships between leukocytes, IL-5 and IL-8 in guinea pig lungs, plasma cortisol and airway function after antigen challenge. Inflamm. Res. 48:41.[Medline]
33. Humbles, A. A., B. Lu, C. A. Nilsson, C. Lilly, E. Israel, Y. Fujiwara, N. P. Gerard, C. Gerard. 2000. A role for the C3a anaphylatoxin in the effector phase of asthma. Nature 406:998.[Medline]

This article has been cited by other articles:

				X. Zhang, I. P. Lewkowich, G. Kohl, J. R. Clark, M. Wills-Karp, and J. Kohl A Protective Role for C5a in the Development of Allergic Asthma Associated with Altered Levels of B7-H1 and B7-DC on Plasmacytoid Dendritic Cells J. Immunol., April 15, 2009; 182(8): 5123 - 5130. [Abstract] [Full Text] [PDF]

				M. Wills-Karp Complement Activation Pathways: A Bridge between Innate and Adaptive Immune Responses in Asthma Proceedings of the ATS, July 1, 2007; 4(3): 247 - 251. [Abstract] [Full Text] [PDF]

				P. Dillard, R. A. Wetsel, and S. M. Drouin Complement C3a Regulates Muc5ac Expression by Airway Clara Cells Independently of Th2 Responses Am. J. Respir. Crit. Care Med., June 15, 2007; 175(12): 1250 - 1258. [Abstract] [Full Text] [PDF]

				C. M. Deaton, L. Deaton, E. Jose-Cunilleras, T. L. Vincent, A. W. Baird, K. Dacre, and D. J. Marlin Early onset airway obstruction in response to organic dust in the horse J Appl Physiol, March 1, 2007; 102(3): 1071 - 1077. [Abstract] [Full Text] [PDF]

				G. A. Melendi, S. J. Hoffman, R. A. Karron, P. M. Irusta, F. R. Laham, A. Humbles, B. Schofield, C.-H. Pan, R. Rabold, B. Thumar, et al. C5 Modulates Airway Hyperreactivity and Pulmonary Eosinophilia during Enhanced Respiratory Syncytial Virus Disease by Decreasing C3a Receptor Expression J. Virol., January 15, 2007; 81(2): 991 - 999. [Abstract] [Full Text] [PDF]

				S. L. Mueller-Ortiz, T. J. Hollmann, D. L. Haviland, and R. A. Wetsel Ablation of the complement C3a anaphylatoxin receptor causes enhanced killing of Pseudomonas aeruginosa in a mouse model of pneumonia Am J Physiol Lung Cell Mol Physiol, August 1, 2006; 291(2): L157 - L165. [Abstract] [Full Text] [PDF]

				C. Taube, J. M. Thurman, K. Takeda, A. Joetham, N. Miyahara, M. C. Carroll, A. Dakhama, P. C. Giclas, V. M. Holers, and E. W. Gelfand Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation PNAS, May 23, 2006; 103(21): 8084 - 8089. [Abstract] [Full Text] [PDF]

				S. M. Drouin, M. Sinha, G. Sfyroera, J. D. Lambris, and R. A. Wetsel A Protective Role for the Fifth Complement Component (C5) in Allergic Airway Disease Am. J. Respir. Crit. Care Med., April 15, 2006; 173(8): 852 - 857. [Abstract] [Full Text] [PDF]

				S.-H. Lee, T. Rhim, Y.-S. Choi, J.-W. Min, S.-H. Kim, S.-Y. Cho, Y.-K. Paik, and C.-S. Park Complement C3a and C4a Increased in Plasma of Patients with Aspirin-induced Asthma Am. J. Respir. Crit. Care Med., February 15, 2006; 173(4): 370 - 378. [Abstract] [Full Text] [PDF]

				M. Schaefer, S. Konrad, J. Thalmann, C. Rheinheimer, K. Johswich, B. Sohns, and A. Klos The Transcription Factors AP-1 and Ets Are Regulators of C3a Receptor Expression J. Biol. Chem., December 23, 2005; 280(51): 42113 - 42123. [Abstract] [Full Text] [PDF]

				C. B. Martin and B. K. Martin Characterization of the Murine C3a Receptor Enhancer-Promoter: Expression Control by an Activator Protein 1 Sequence and an Ets-Like Site J. Immunol., September 1, 2005; 175(5): 3123 - 3132. [Abstract] [Full Text] [PDF]

				R. Baelder, B. Fuchs, W. Bautsch, J. Zwirner, J. Kohl, H. G Hoymann, T. Glaab, V. Erpenbeck, N. Krug, and A. Braun Pharmacological Targeting of Anaphylatoxin Receptors during the Effector Phase of Allergic Asthma Suppresses Airway Hyperresponsiveness and Airway Inflammation J. Immunol., January 15, 2005; 174(2): 783 - 789. [Abstract] [Full Text] [PDF]

				M. M. Marc, P. Korosec, M. Kosnik, I. Kern, M. Flezar, S. Suskovic, and J. Sorli Complement Factors C3a, C4a, and C5a in Chronic Obstructive Pulmonary Disease and Asthma Am. J. Respir. Cell Mol. Biol., August 1, 2004; 31(2): 216 - 219. [Abstract] [Full Text] [PDF]

				J. Ahamed, R. T. Venkatesha, E. B. Thangam, and H. Ali C3a Enhances Nerve Growth Factor-Induced NFAT Activation and Chemokine Production in a Human Mast Cell Line, HMC-1 J. Immunol., June 1, 2004; 172(11): 6961 - 6968. [Abstract] [Full Text] [PDF]

				J.-W. Park, C. Taube, A. Joetham, K. Takeda, T. Kodama, A. Dakhama, G. McConville, C. B. Allen, G. Sfyroera, L. D. Shultz, et al. Complement Activation Is Critical to Airway Hyperresponsiveness after Acute Ozone Exposure Am. J. Respir. Crit. Care Med., March 15, 2004; 169(6): 726 - 732. [Abstract] [Full Text] [PDF]

				C. Taube, Y.-H. Rha, K. Takeda, J.-W. Park, A. Joetham, A. Balhorn, A. Dakhama, P. C. Giclas, V. M. Holers, and E. W. Gelfand Inhibition of Complement Activation Decreases Airway Inflammation and Hyperresponsiveness Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1333 - 1341. [Abstract] [Full Text] [PDF]

				E. P. Grant, D. Picarella, T. Burwell, T. Delaney, A. Croci, N. Avitahl, A. A. Humbles, J.-C. Gutierrez-Ramos, M. Briskin, C. Gerard, et al. Essential Role for the C5a Receptor in Regulating the Effector Phase of Synovial Infiltration and Joint Destruction in Experimental Arthritis J. Exp. Med., December 2, 2002; 196(11): 1461 - 1471. [Abstract] [Full Text] [PDF]

				S. M. Drouin, D. B. Corry, T. J. Hollman, J. Kildsgaard, and R. A. Wetsel Absence of the Complement Anaphylatoxin C3a Receptor Suppresses Th2 Effector Functions in a Murine Model of Pulmonary Allergy J. Immunol., November 15, 2002; 169(10): 5926 - 5933. [Abstract] [Full Text] [PDF]

				D. M. Walters, P. N. Breysse, B. Schofield, and M. Wills-Karp Complement Factor 3 Mediates Particulate Matter-Induced Airway Hyperresponsiveness Am. J. Respir. Cell Mol. Biol., October 1, 2002; 27(4): 413 - 418. [Abstract] [Full Text] [PDF]

				R. Venkayya, M. Lam, M. Willkom, G. Grunig, D. B. Corry, and D. J. Erle The Th2 Lymphocyte Products IL-4 and IL-13 Rapidly Induce Airway Hyperresponsiveness Through Direct Effects on Resident Airway Cells Am. J. Respir. Cell Mol. Biol., February 1, 2002; 26(2): 202 - 208. [Abstract] [Full Text] [PDF]

				A. Burke-Gaffney, K. Blease, A. Hartnell, and P. G. Hellewell TNF-{alpha} Potentiates C5a-Stimulated Eosinophil Adhesion to Human Bronchial Epithelial Cells: A Role for {alpha}5{beta}1 Integrin J. Immunol., February 1, 2002; 168(3): 1380 - 1388. [Abstract] [Full Text] [PDF]

				N. KRUG, T. TSCHERNIG, V. J. ERPENBECK, J. M. HOHLFELD, and J. KOHL Complement Factors C3a and C5a Are Increased in Bronchoalveolar Lavage Fluid after Segmental Allergen Provocation in Subjects with Asthma Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1841 - 1843. [Abstract] [Full Text] [PDF]

				S. M. Drouin, D. B. Corry, J. Kildsgaard, and R. A. Wetsel Cutting Edge: The Absence of C3 Demonstrates a Role for Complement in Th2 Effector Functions in a Murine Model of Pulmonary Allergy J. Immunol., October 15, 2001; 167(8): 4141 - 4145. [Abstract] [Full Text] [PDF]

				M. Abe, K. Shibata, H. Akatsu, N. Shimizu, N. Sakata, T. Katsuragi, and H. Okada Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats J. Immunol., October 15, 2001; 167(8): 4651 - 4660. [Abstract] [Full Text] [PDF]

				R. S. Ames, D. Lee, J. J. Foley, A. J. Jurewicz, M. A. Tornetta, W. Bautsch, B. Settmacher, A. Klos, K. F. Erhard, R. D. Cousins, et al. Identification of a Selective Nonpeptide Antagonist of the Anaphylatoxin C3a Receptor That Demonstrates Antiinflammatory Activity in Animal Models J. Immunol., May 15, 2001; 166(10): 6341 - 6348. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bautsch, W. Articles by Köhl, J. Search for Related Content PubMed PubMed Citation Articles by Bautsch, W. Articles by Köhl, J. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Asthma